Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teladoc Health Inc (TDOC) vs Veritone Inc (VERI) Price & Performance

Teladoc Health IncTrade
Veritone IncTrade

Price performance (Past 24H)

Key statistics

Teladoc Health Inc vs Veritone Inc — how do they compare? Teladoc Health Inc trades at $5.65 (market cap $1.01B), while Veritone Inc trades at $0.58 (market cap $59.46M). The key difference: Teladoc Health Inc is far larger — about 17× Veritone Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Teladoc Health Inc for 39 Days and Veritone Inc for 12 Days on average.

TDOCVERI
Market Cap
$1.01B$59.46M
Volume
4,668,47715,523,164
Sector
HealthTechnology
52-Week High
$9.72$8.39
52-Week Low
$4.47$0.59
Typical Hold Time
39 Days12 Days
Enterprise Value
$1.27B$94.86M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teladoc Health Inc

Teladoc Health (TDOC) trades at $5.67, showing modest daily gains but remains near multi-year lows with a bearish technical outlook. The company maintains strong revenue around $2.5B annually but continues to report net losses, with a -7.13% net margin in 2026. Recent management changes include the appointment of a new CFO, while analyst sentiment remains cautious despite a consensus price target of $8.83 representing 56% upside potential.

TDOC presents a high-risk opportunity with significant upside potential if the company can achieve profitability turnaround. The stock trades at discounted valuations (P/S 0.4x, P/B 0.77x) but faces execution risks from ongoing losses, BetterHelp segment challenges, and potential legal investigations. Free cash flow generation and integrated care growth provide stabilization, though sustained profitability remains the key catalyst needed for sustained recovery.

Veritone Inc

Veritone (VERI) trades at $0.61, down 11.76% in the last 24 hours, reflecting bearish technical signals. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow challenges, though revenue remains near $92 million. Recent news includes a $15 million equity offering and partnerships, but legal investigations and persistent losses weigh on sentiment.

The outlook is highly speculative, with a consensus price target of $3.75 suggesting significant upside if the company achieves profitability. However, high execution risk, cash burn, and legal overhangs present substantial downside, making the stock suitable only for risk-tolerant investors betting on a turnaround.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

TDOC

No sentiment data available yet.

VERI
7% Buy93% Sell
Avg holding period · 12 Days

About Teladoc Health Inc

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.

Read more on TDOC →

About Veritone Inc

Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.

Read more on VERI →